NasdaqGM - Delayed Quote USD

PowerUp Acquisition Corp. (PWUPW)

Compare

0.0475

0.0000

(0.00%)

At close: January 3 at 4:00:00 PM EST

Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements

Highlights Transaction Valuation: The transaction values Aspire Biopharma, Inc. at a pre-money equity value of approximately $316 million.Industry-Leading Platform: Aspire is focused on developing a pipeline of products utilizing its novel delivery mechanisms to enhance the efficacy of “do no harm” FDA approved drugs, nutraceuticals and supplements.Innovative Drug Delivery Technology: Aspire’s patented and patent-pending delivery system includes components specifically formulated to allow rapid

GlobeNewswire 3 months ago

PWUP
-0.78%
PWUPU
-0.52%
PWUPW
0.00%
Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.

Humacao, PR and New York, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of a multi-faceted patent protected disruptive drug delivery mechanism technology, and PowerUp Acquisition Corp. (Nasdaq: PWUP), a Nasdaq Global Market® listed special purpose acquisition company ("PowerUp"), today announced that they have signed a non-binding letter of intent ("LOI") for a potential business combination ("Business Combination"). Under the terms of the

GlobeNewswire 5 months ago

PWUP
-0.78%
PWUPU
-0.52%
PWUPW
0.00%
PowerUp Acquisition Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

New York, NY, June 05, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (the “Company”) (Nasdaq: PWUP) announced today that, on June 3, 2024, the Company received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that the Company was not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic reports with the Se

GlobeNewswire 6 months ago

PWUP
-0.78%
PWUPU
-0.52%
PWUPW
0.00%
PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders

New York, NY, May 20, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (the “Company”) (Nasdaq: PWUP) announced today that its extraordinary general meeting of shareholders (the “Meeting”), which was originally scheduled for May 17, 2024 and postponed to May 21, 2024, has been further postponed to 2:00 p.m. Eastern Time, on Wednesday, May 22, 2024. At the Meeting, the Company’s shareholders will be asked to vote on a proposal to approve, among other things, extending the date by which the Comp

GlobeNewswire 7 months ago

PWUP
-0.78%
PWUPU
-0.52%
PWUPW
0.00%
PowerUp Acquisition Corp. and Visiox Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form S-4 to the SEC in Connection with the Previously Announced Proposed Business Combination

Tarrytown, NY and New York, NY, Jan. 29, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (“PowerUp”) (Nasdaq: PWUP) and Visiox Pharmaceuticals, Inc. (“Visiox”), a commercial-stage biopharmaceutical company, today announced that PowerUp has filed with the U.S. Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 in connection with the previously announced proposed business combination between PowerUp and Visiox (the “Business Combination” or the “Transaction”). The c

GlobeNewswire 11 months ago

PWUP
-0.78%
PWUPU
-0.52%
PWUPW
0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PowerUp Acquisition Corp. (PWUPW)

Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements

Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp.

PowerUp Acquisition Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders

PowerUp Acquisition Corp. and Visiox Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form S-4 to the SEC in Connection with the Previously Announced Proposed Business Combination